It appears problems at Novo Nordisk’s recently acquired manufacturing facility in Indiana aren’t going to be solved any time soon. The FDA has tagged the former Catalent facility with an official ...

Novo Nordisk has struck a deal to buy Akero Therapeutics for up to $5.2 billion, teeing up a showdown with Roche and others in a blockbuster liver disease market. Akero confirmed its status as a key ...

Novo Nordisk's potential layoffs come as the pharmaceutical major, which has developed the weight-loss drug Wegovy, seeks to reduce costs amid a fierce battle with Eli Lilly for the weight-loss drug ...

Oct 10 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab has decided to discontinue its cell therapy research and development efforts, a spokesperson for the Danish drugmaker told Reuters on Friday.

Novo Nordisk is drawing divided views from Wall Street analysts. Some may be disappointed by the loss of market share to Eli Lilly. Three events could turn sentiment positive in the coming months. The ...

LONDON/COPENHAGEN, Oct 15 (Reuters) - Romel Amineh is one of a fast-growing group of Novo Nordisk workers in Denmark laid off as the drugmaker battles to cut costs and revive its fortunes in a ...

Novo Nordisk (NYSE:NVO) shares have moved little in recent sessions, with investors taking a wait-and-see approach. Market participants are weighing the company's recent performance metrics against ...

Novo Nordisk's acquisition of Akero Therapeutics includes efruxifermin, a potential best-in-class treatment for MASH, aligning with its strategy to address diabetes and obesity-related comorbidities.

Novo Nordisk is ending all work in cell therapy, including a Type 1 diabetes program, amid CEO Maziar Mike Doustdar's reorganization. As part of the move, the company is laying off nearly all of the ...

Novo Nordisk NOVO.B-0.54%decrease; red down pointing triangle said it would take over a drug under development to treat rare blood and kidney disorders from Nasdaq-listed biopharmaceutical firm Omeros ...

Ozempic maker Novo Nordisk (NVO) is closing its cell therapy division as part of a major restructuring drive initiated under the company’s new CEO, Mike Doustdar, Bloomberg News reported on Thursday, ...